Figure 7

GAS5 in combination with gefitinib suppresses the growth of EGFR inhibitor-resistant tumor xenografts in vivo. (A) All the tumors after removal from the mice after 30 days. (B) qRT-PCR analysis of GAS5 expression in tumor tissues formed from four groups, and qRT-PCR analyses indicated that GAS5 expression is significantly increased in vivo. (C) Tumor weight when the tumors were harvested. The data represent the mean ± SD. (D) Tumor growth curve. Six mice per group were used in the xenograft experiment. The tumor volumes of mice were measured. *P < 0.05, for comparisons with gefitinib alone. (E) The gefitinib treatments did not cause significant body weight loss in the tested mice.